Blast Crisis, Leukemia, Leukemia, Lymphocytic, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Conditions
Keywords
Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Leukemia, Lymphocytic
Brief summary
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.
Interventions
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia. * Life expectancy of 12 weeks or greater. * ECOG Performance Status less than or equal to 2. * Meets protocol requirements for specified laboratory values. * No manifestations of a malabsorption syndrome.
Exclusion criteria
* Patients who have received more than three chemotherapy regimens for more than three recurrences of the disease. * Poor medical risks because of nonmalignant systemic disease as well as those with active uncontrolled conditions. * Patients who have received investigational therapy of any type within 30 days prior to administration.
Outcome results
None listed